Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Delstrigo in virologically controlled HIV-1 with historical M184V/I mutation
2023-505845-17-00Phase 2Authorised
- Sponsor
- CHU Caen Normandie
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by CHU Caen Normandie. Primary endpoint: Proportion of patients with undetectable viral load at 24 weeks (per-protocol). Planned start Nov 2023; status: authorised.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2023-505845-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505845-17-00.